NOTV Stock - Inotiv, Inc.
Unlock GoAI Insights for NOTV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $513.02M | $490.74M | $572.42M | $547.66M | $89.61M |
| Gross Profit | $65.05M | $111.17M | $165.44M | $157.21M | $30.16M |
| Gross Margin | 12.7% | 22.7% | 28.9% | 28.7% | 33.7% |
| Operating Income | $-30,902,000 | $-86,406,000 | $-81,460,000 | $-27,447,000 | $1.53M |
| Net Income | $-68,625,000 | $-108,445,000 | $-105,140,000 | $-337,262,000 | $10.89M |
| Net Margin | -13.4% | -22.1% | -18.4% | -61.6% | 12.2% |
| EPS | $-2.11 | $-4.19 | $-4.10 | $-13.85 | $0.83 |
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 14th 2024 | Jefferies | Downgrade | Hold | $3.75← $11.5 |
| February 9th 2024 | Jefferies | Upgrade | Buy | $11.5← $3 |
| July 20th 2023 | Wells Fargo | Initiation | Overweight | $9 |
| January 19th 2023 | Jefferies | Downgrade | Hold | $8← $10 |
| January 11th 2023 | Lake Street | Upgrade | Buy | $10← $4 |
| November 18th 2022 | Lake Street | Downgrade | Hold | $7← $60 |
| October 4th 2022 | Jefferies | Initiation | Buy | $27 |
Earnings History & Surprises
NOTVEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | — | — | — | — |
Q4 2025 | Dec 3, 2025 | $-0.08 | $-0.14 | -75.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.24 | $-0.18 | +25.0% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $-0.42 | $-0.42 | 0.0% | = MET |
Q4 2024 | Dec 3, 2024 | $-0.91 | $-0.16 | +82.4% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.09 | $-0.20 | -122.2% | ✗ MISS |
Q2 2024 | May 15, 2024 | $0.05 | $-0.29 | -680.0% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $0.07 | $-0.60 | -957.1% | ✗ MISS |
Q4 2023 | Dec 11, 2023 | $0.11 | $-0.29 | -363.6% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.10 | $0.07 | +170.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.16 | $-0.34 | -112.5% | ✗ MISS |
Q1 2023 | Jan 10, 2023 | $-0.37 | $-0.09 | +75.7% | ✓ BEAT |
Q4 2022 | Dec 12, 2022 | $-0.37 | $-9.54 | -2478.4% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.04 | $-0.15 | -300.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.27 | $-0.24 | +11.1% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $0.16 | $-0.54 | -437.5% | ✗ MISS |
Q4 2021 | Dec 16, 2021 | $-0.14 | $-0.34 | -142.9% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.08 | $-0.08 | 0.0% | = MET |
Latest News
Lake Street Maintains Buy on Inotiv, Lowers Price Target to $3
➖ NeutralInotiv Q4 EPS $(0.25) Beats $(0.46) Estimate, Sales $138.142M Beat $135.605M Estimate
📈 PositiveFinancial Times Reported FDA To End Requirement For Lab Monkeys In Some Drug Safety Studies
➖ Neutral'CDC to end all monkey research; Studies Related To HIV And Other Infectious Diseases Will Be Phased Out, Sources Say; Fate Of The Agency's Animals Remains Unclear'- Science
📉 NegativeNOTV stock has given up its prior gain. Inotiv shares were trading higher after the company reported preliminary Q4 and FY25 revenue results.
➖ NeutralInotiv shares are trading higher after the company reported preliminary Q4 and FY25 revenue results.
📈 PositiveInotiv Announces Preliminary Expected Q4 Revenue Of $137.5M - $138.5M And Preliminary Expected FY25 Revenue Of $512.5M - $513.5M
📈 PositiveInotiv Says Timeline For Completion Of Restoration Efforts Related To Cybersecurity Incident Is Not Yet Known; Not Yet Determined If 2025 Cybersecurity Incident Is Likely To Have Material Impact
📉 NegativeInotiv Enters Settlement Agreement For Securities Class Action; 2025 Cybersecurity Incident Is Expected To Continue To Cause, Disruptions To Certain Business Operations Of Co; To Pay $8.75M Cash Settlement
📉 NegativeInotiv Files For Mixed Shelf Offering Of Up To $350.0M
📉 NegativeInotiv Became Aware Of A Cybersecurity Incident Affecting Certain Of Its Systems And Data; The Cybersecurity Incident Has Caused, And Is Expected To Continue To Cause, Disruptions To Certain Business Operations Of The Company
📉 NegativeFrequently Asked Questions about NOTV
What is NOTV's current stock price?
What is the analyst price target for NOTV?
What sector is Inotiv, Inc. in?
What is NOTV's market cap?
Does NOTV pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NOTV for comparison